Senores Pharmaceuticals
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Senores Pharmaceuticals is strategically pivoting towards a high-value, niche-focused business model, which is expected to drive significant revenue growth over the next 12-24 months. Management's optimistic outlook is supported by a robust pipeline of over 100 product strengths and an aggressive launch strategy, including 35 approved ANDAs in the US and over 500 products in emerging markets. This diversification, coupled with the integration of recent acquisitions and a focus on high-barrier segments, positions the company to capture higher-margin opportunities. However, while revenue growth is forecasted to accelerate, margins are anticipated to remain under pressure due to rising input costs and pricing challenges in the US market. The favorable currency depreciation and resilient demand in chronic therapies provide additional tailwinds, although geopolitical risks and regulatory complexities present notable headwinds. Overall, Vista's financial outlook reflects a strong revenue CAGR of 35% over the next three years, with a target price of INR 2676.21 for the next 12 months, indicating an expected upside of approximately 87%. The company's strategic initiatives and market expansion plans are critical to sustaining growth and improving profitability in a competitive landscape
Why We Like This Stock
- Strategic pivot towards high-value, niche-focused products enhances revenue potential
- Robust pipeline with over 100 product strengths and aggressive launch strategy supports strong growth outlook
- Favorable currency depreciation and resilient demand in chronic therapies bolster revenue stability
Things To Watch Out For
- Rising input costs and pricing pressures in the US market may impact profit margins
- Geopolitical risks and regulatory complexities could hinder operational execution
- Increased competition in the biosimilars space may affect profitability and market share
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 215 | 398 | 633 | 865 | 1,462 |
| Profit Before Tax (Cr.) | 25 | 71 | 159 | 233 | 388 |
| PBT Margin | 11.6% | 17.8% | 25.1% | 27.0% | 26.5% |
| Net Profit (Cr.) | 17 | 55 | 140 | 204 | 324 |
| Earnings Per Share | 3.5 | 11.9 | 29.1 | 42.4 | 70.5 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Choice Equity | ▲ Buy | 1,795 | 28-Jul-2026 |
Company Overview
Show Company Profile
Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, neurology, antacid, and vitamin and mineral preparation solutions; and analgesic/anti-inflammatory/antipyretic, anti-diabetic, antimalarial, nutritional supplements, and urinary tract generics, as well as management and consultancy services. The company was incorporated in 2017 and is based in Ahmedabad, India.